A Phase II Study Evaluating the Association of Topotecan and Lapatinib in Early Recurrent (Less Than 12 Months) Ovarian or Peritoneal Cancer Patients After First Line of Platinum-Based Chemotherapy

Trial Profile

A Phase II Study Evaluating the Association of Topotecan and Lapatinib in Early Recurrent (Less Than 12 Months) Ovarian or Peritoneal Cancer Patients After First Line of Platinum-Based Chemotherapy

Discontinued
Phase of Trial: Phase II

Latest Information Update: 21 Jan 2013

At a glance

  • Drugs Lapatinib (Primary) ; Topotecan (Primary)
  • Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
  • Focus Therapeutic Use
  • Acronyms TOPO-LAPA
  • Most Recent Events

    • 04 May 2009 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top